For approximately €76.8mm ($60mm) (including assets, fees, and earn-outs), bioMerieux has sold its hemostasis product line to diagnostic testing company Trinity Biotech PLC . (May)
Along with a wide range of reagents that analyze blood clotting parameters, Trinity gets the MDA hemostasis and thrombosis analyzer, the MTX medium-volume automated hemostasis system, and the Thrombolyzer high-volume...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?